EAM Global Investors’s Standard BioTools LAB Stock Holding History

EAM Global Investors’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-95,960	Closed	-$1.18M	–	137
2019 Q2	$1.18M	Sell	95,960 -63,539	-40%	-$809K	0.5%	114
2019 Q1	$2.12M	Hold	159,499	–	–	0.94%	27
2018 Q4	$1.38M	Buy	+159,499	New	+$1.24M	0.75%	66

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

EAM Global Investors's LAB Position: Q3 2019 in Review

EAM Global Investors sold out of Standard BioTools (LAB) in Q3 2019, closing a stake of 95,960 shares — an estimated $1.18M sold.

EAM Global Investors first reported a position in LAB in Q4 2018 and held it in 3 quarters. The position peaked at $2.12M in Q1 2019. 125 funds tracked by Wall St. Rank hold LAB as of Q3 2019.

EAM Global Investors reported no remaining Standard BioTools position as of Q3 2019 after selling out during the quarter.
EAM Global Investors sold 95,960 Standard BioTools shares in Q3 2019, an estimated $1.18M.
EAM Global Investors first reported a position in Standard BioTools in Q4 2018 and held it in 3 quarters.
EAM Global Investors's Standard BioTools position peaked at $2.12M in Q1 2019.
125 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2019.

Based on EAM Global Investors's 13F filing for Q3 2019, filed 13 Nov 2019.